Advertisement


Jennifer Yon-Li Wo, MD, on Colorectal and Pancreatic Cancers: New Findings on SBRT With Ipilimumab and Nivolumab

2024 ASCO GI Cancers Symposium

Advertisement

Jennifer Yon-Li Wo, MD, of Massachusetts General Hospital, discusses the local failure rate of non-ablative hypofractionated radiation therapy in combination with the immune checkpoint inhibitors ipilimumab and nivolumab compared to ablative SBRT to treat metastatic microsatellite-stable colorectal and pancreatic cancers as a secondary analysis of four prospective trials. Dr. Wo and her team found that, despite using nearly half the radiation dose in those who received immunotherapy, there was no significant difference in local failure rates (Abstract 752).



Related Videos

Hepatobiliary Cancer

Riccardo Lencioni, MD, on Hepatocellular Carcinoma: Transarterial Chemoembolization, Durvalumab, and Bevacizumab

Riccardo Lencioni, MD, of the University of Pisa School of Medicine, discusses phase III results from the EMERALD-1 study of durvalumab plus bevacizumab plus TACE (transarterial chemoembolization) in patients with embolization-eligible unresectable hepatocellular carcinoma. Compared with TACE alone, this combination is the first immune checkpoint inhibitor–based regimen to improve progression-free survival and has the potential to set a new standard of care in this disease, according to Dr. Lencioni (Abstract LBA432).

Gastroesophageal Cancer

Ken Kato, MD, PhD, on Advanced Esophageal Cancer: Biomarker Analyses From CheckMate 648

Ken Kato, MD, PhD, of Japan’s National Cancer Center Hospital, discusses the first comprehensive findings on biomarkers from the CheckMate 648 study. These results further corroborate the clinical efficacy of nivolumab plus chemotherapy and nivolumab plus ipilimumab in the first-line treatment of advanced esophageal squamous cell carcinoma. According to Dr. Kato, the data suggest an overall survival benefit across multiple biomarker subgroups (Abstract 252).

Pancreatic Cancer

Frank Kullmann, MD, on Metastatic Pancreatic Cancer: Recent Data on Gemcitabine and Nab-Paclitaxel

Frank Kullmann, MD, of Germany’s Klinikum Weiden, discusses results from the ALPACA trial, which suggest a dose-reduced regimen with alternating cycles of gemcitabine/nab-paclitaxel and gemcitabine monotherapy after three induction cycles of standard gemcitabine/nab-paclitaxel is feasible and associated with an overall survival comparable to that with standard treatment, as well as improved tolerability (Abstract 605).

Gastroesophageal Cancer
Gastrointestinal Cancer

Anant Ramaswamy, DM, on Advanced Gastric Cancers: New Findings on Adding Docetaxel to Doublet

Anant Ramaswamy, DM, of Tata Memorial Centre, discusses phase III results of a study that added docetaxel to a doublet regimen of fluorouracil or capecitabine and oxaliplatin, which did not improve overall survival in patients with advanced gastroesophageal junction and gastric cancers. Continuing chemotherapy beyond 6 months also did not appear to improve survival in this population (Abstract LBA248).

Colorectal Cancer

Dominik P. Modest, MD, on Colorectal Cancer: Health-Related Quality-of-Life Findings From CodeBreaK 300

Dominik P. Modest, MD, of Charité-Universitätsmedizin Berlin, discusses phase III study findings showing sotorasib plus panitumumab vs trifluridine/tipiracil or regorafenib benefits patients with chemorefractory metastatic colorectal cancer in terms of improved clinical outcomes and better self-reported quality of life (Abstract 10).

Advertisement

Advertisement




Advertisement